Cargando…
Update to Drugs, Devices, and the FDA: How Recent Legislative Changes Have Impacted Approval of New Therapies
Two major legislative actions since 2015, the 21st Century Cures Act of 2016 and the U.S. Food and Drug Administration (FDA) Reauthorization Act of 2017, contain significant provisions that potentially streamline drug development times, and by extension, may reduce costs. Evidence suggests, however,...
Autor principal: | Van Norman, Gail A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444905/ https://www.ncbi.nlm.nih.gov/pubmed/32864509 http://dx.doi.org/10.1016/j.jacbts.2020.06.010 |
Ejemplares similares
-
Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016) -
Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs
por: Van Norman, Gail A.
Publicado: (2016) -
Drugs and Devices: Comparison of European and U.S. Approval Processes
por: Van Norman, Gail A.
Publicado: (2016) -
Expanded Patient Access to Investigational New Devices: Review of Emergency and Nonemergency Expanded Use, Custom, and 3D-Printed Devices
por: Van Norman, Gail A.
Publicado: (2018) -
Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the “Right to Try”
por: Van Norman, Gail A.
Publicado: (2018)